* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Ref: SAMHSA - Temple University Sites
Survey
Document related concepts
Drug design wikipedia , lookup
Electronic prescribing wikipedia , lookup
Compounding wikipedia , lookup
Drug discovery wikipedia , lookup
Prescription costs wikipedia , lookup
Drug interaction wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Neuropharmacology wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Dextropropoxyphene wikipedia , lookup
Adherence (medicine) wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Theralizumab wikipedia , lookup
Transcript
Benjamin J. Pariser, DO RASE Physician Overview This presentation will review the option of Medication Assisted Treatment as part of a comprehensive recovery program. Goals 1. Understand the core principles of opioid addiction, which are central to the rapidly growing epidemic of opioid abuse, dependence and overdose. 2. Describe classes of medications available for medication assisted treatment and recovery 3. Explain the role of medications as part of a comprehensive treatment plan Opioid Epidemic Statistics Drug overdoses killed 47,000 people in the US in 2014 130 deaths per day, on average 29,000, or 80 per day – involved an opioid Stigma and inadequate access to treatment are the biggest barriers to overcoming the ongoing crisis. Ref: A deadly crisis: mapping the spread of America's drug overdose epidemic By Nadja Popovich; Additional development by Rich Harris. Source: Centers for Disease Control and Prevention and the National Center for Health Statistics Overdose Deaths Opioid Statistics Opioid Addiction Medication Assisted Treatments Medication-Assisted Treatment for Opioid Addiction (MAT): A type of addiction treatment that involves the following: Provided in a certified, licensed opioid treatment program or a physician’s office Provides maintenance pharmacotherapy using an opioid agonist, a partial agonist, or an antagonist medication May be combined with other comprehensive treatment services, including medical and psychosocial services. Ref: Substance Abuse and Mental Health Services Administration (SAMHSA) Medications Opioid agonist treatment Methadone Buprenorphine products Buprenorphine/naloxone (Suboxone) Buprenorphine (Subutex) Opioid antagonist treatment Naltrexone for extended- release injectable suspension (Vivitrol) Naloxone (Narcan) Methadone Is the most frequently used medication for opioid addiction treatment in opioid treatment programs (OTPs) Is a synthetic long-acting medication Comes in several formulations, including oral solution, liquid concentrate, tablet/diskette, and powder Is a full opioid agonist that decreases the pain-killing and other effects of opioids Was never formally approved by the Food and Drug Administration (FDA) Is a Drug Enforcement Administration (DEA) Schedule II drug Is available in outpatient treatment programs. Patients typically must go to appointments daily Potential for home use (7-30 days) Ref: SAMHSA Methadone Pros Very long half life Effective Liquid or tablets Cons Overdose potential Risk of fatal arrhythmias Drug interactions Strong Inter-patient variability in absorption, metabolism, and relative analgesic potency. Buprenorphine Products Does not activate mu receptors fully(partial agonist), so larger doses of buprenorphine do not produce greater agonist effects (Ceiling effect) Has an increased margin of safety from death by respiratory depression when increased doses of buprenorphine are used Was approved by the FDA in 2002 Is a DEA Schedule III drug Can be administered in a physician’s office, OTP, or other medical settings. Ref: SAMHSA Buprenorphine Products Buprenorphine/Naloxone Brand names Suboxone and Zubsolv Is formulated as a sublingual tablet and film Was approved by the FDA in 2002 Is a DEA Schedule III drug Is administered in a physician’s office, an OTP, or another healthcare setting. Why is Naloxone in Suboxone? Added solely to prevent IV abuse Naloxone is a water-soluble molecule that does not pass through the membranes lining the mouth Buprenorphine is a fat soluble molecule that does pass through the membranes of the mouth Neither substance takes effect if swallowed because it is removed quickly by the liver (first pass effect) Ref: J.T. Junig, MD, PhD Buprenorphine Pros Less clinic attendance Can be prescribed in physician office – less stigma Ceiling effect Cons Street value Potential for abuse Difficult to adhere to the withdrawal protocol COWS: Clinical Opiate Withdrawal Scale Buprenorphine Protocol Induction Patient must be in withdrawal to begin induction Depends on clinic protocol Seeking dose that relieves withdrawal symptoms The Induction Phase is the medically monitored startup of buprenorphine treatment performed in a qualified physician’s office or certified OTP using approved buprenorphine products. The medication is administered when a person with an opioid dependency has abstained from using opioids for 12 to 24 hours and is in the early stages of opioid withdrawal. It is important to note that buprenorphine can bring on acute withdrawal for patents who are not in the early stages of withdrawal and who have other opioids in their bloodstream. Ref: SAMHSA Buprenorphine Protocol Stabilization The Stabilization Phase begins after a patient has discontinued or greatly reduced their misuse of the problem drug, no longer has cravings, and experiences few, if any, side effects. The buprenorphine dose may need to be adjusted during this phase. Because of the long-acting agent of buprenorphine, once patients have been stabilized, they can sometimes switch to alternate-day dosing instead of dosing every day. Seeking dose that alleviates cravings Ref: SAMHSA Buprenorphine Protocol Maintenance The Maintenance Phase occurs when a patient is doing well on a steady dose of buprenorphine. The length of time of the maintenance phase is tailored to each patient and could be indefinite. Once an individual is stabilized, an alternative approach would be to go into a medically supervised withdrawal, which makes the transition from a physically dependent state smoother. People then can engage in further rehabilitation—with or without MAT—to prevent a possible relapse. Ref: SAMHSA Buprenorphine Protocol Medically Supervised Withdrawal Individualized withdrawal according to each patient’s needs Ongoing counseling and development of support network No set timeframe/dose reduction Depends on clinic philosophy Continual monitoring for risk of relapse Ref: BupPractice Buprenorphine Subutex Used in pregnancy and nursing Risk of abuse Naltrexone: Vivitrol Is a highly effective opioid antagonist Approved by the FDA for maintenance treatment in 1984 No narcotic effect and produces no withdrawal symptoms when a patient stops using it No abuse potential; tolerance does not develop even after months of regular use Is formulated as an oral tablet and depot injection Blocks the effects of heroin, morphine, and methadone Displaces buprenorphine to a lesser degree, but in high enough doses overrides buprenorphine’s activity as well Despite its potential advantages, has had little effect on the treatment of opioid addiction in the United States, primarily because of poor patient compliance Is not on the DEA schedule Is available in physicians’ offices, OTPs, and other substance abuse treatment programs. Ref: SAMHSA Tolerance Tolerance occurs when the person no longer responds to the drug in the way that person initially responded. Stated another way, it takes a higher dose of the drug to achieve the same level of response achieved initially. Ref: National Institute on Drug Abuse (NIDA) The Faces of Addiction Bridget – 26 year old female Lynne – 34 year old female George – 35 year old male Tracey – 23 year old female Bob – 24 year old male Questions